Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
Authors:
- Olga BraginaOBOlga Bragina
- Alexey SchulgaASAlexey Schulga
- Elena KonovalovaEKElena Konovalova
- Eugeniy GarbukovEGEugeniy Garbukov
- Anzhelika VorobyevaAVAnzhelika Vorobyeva
- Anna OrlovaAOAnna Orlova
- Liubov TashirevaLTLiubov Tashireva
- Jens SörensenJSJens Sörensen
- Anna MedvedevaAMAnna Medvedeva
- Sergey DeyevSDSergey Deyev
- 12 August 2021
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 63 (4) , 528-535
Abstract
Radionuclide molecular imaging of human epidermal growth factor type 2 (HER2) expression may enable a non-invasive discrimination between HER2-positive and HER2-negative breast cancers for stratification of patients for HER2-targeted treatments. DARPin G3 is a small (molecular weigh 14 kDa) scaffold protein with picomolar affinity to HER2. The aim of this first-in-human study was to evaluate the safety, biodistribution and dosimetry of 99mTc-(HE)3-G3. Methods: Three cohorts of patients with primary breast cancer (each including at least 4 patients with HER2-negative and 5 patients with HER2-positive tumors) were injected with either 1000, 2000 or 3000 µg of 99mTc-(HE)3-G3 (287±170 MBq). Whole-body planar imaging followed by SPECT was performed at 2, 4, 6 and 24 h after injection. Vital signs and possible side effects were monitored during imaging and up to 7 days after injection. Results: All injections were well tolerated. No side effects were observed. The results of blood and urine analyses did not differ before and after studies. 99mTc-(HE)3-G3 cleared rapidly from the blood. The highest uptake was detected in the kidneys and liver followed by the lungs, breasts and small intestinal content. The hepatic uptake after injecting with 2000 or 3000 µg was significantly (p99mTc-(HE)3-G3 is safe, well-tolerated and provides a low absorbed dose burden on patients. This imaging enables discerning HER2-positive and HER2-negative breast cancer. Phase I study data justifies further clinical development of 99mTc-(HE)3-G3.Keywords
This publication has 20 references indexed in Scilit:
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer PatientsJournal of Nuclear Medicine, 2016
- Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CTTheranostics, 2016
- Development of Companion DiagnosticsSeminars in Nuclear Medicine, 2016
- Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registryAnnals of Oncology, 2015
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialAnnals of Oncology, 2015
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2015
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapyAnnual Review of Pharmacology and Toxicology, 2015
- Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2Journal of Molecular Biology, 2007
- Targeted Therapy in Breast CancerMolecular & Cellular Proteomics, 2004